Youngkin signs several maternal health bills, tweaks another on unconscious bias training
Gov. Glenn Youngkin signed several bills aimed at improving maternal health in the commonwealth, building on promises both he and Democratic leadership made to support parents and health care workers.
Dubbed the 'Momnibus' package, the Democrat-led bills stem from a Black Maternal Health Summit hosted last year in the state Capitol that brought medical professionals, advocates and lawmakers from across the state and beyond for roundtable discussions and panels. Alongside these conversations, a rural health committee spent months touring Virginia, gathering firsthand accounts of maternal care gaps in underserved communities.
Resulting legislation included bills aimed at addressing disparities, from requiring implicit bias training for medical license renewals to strengthening obstetrics training in hospitals and expanding support for midwives and doulas.
While the state has previously allocated funding to boost OB-GYN and family practice medical residencies in the state, maternal healthcare workers like midwives and doulas are more likely to live longer-term in the areas that they serve. Both are key players in filling rural health care gaps as well as addressing health care disparities for patients of color.
To that end, Youngkin has signed Senate Bill 1352 and House Bill 1635, which build on a 2021 law that allowed some midwives to establish private practices after completing 1,000 training hours under agreements with other physicians. The new bills, by Sen. Kannan Srinivasan, D-Loudoun, and Del. Joshua Cole, D-Spotsylvania, respectively, will extend that opportunity to other types of midwives.
Youngkin signs bill to protect reproductive and sexual health data, vetoes right to contraception
Relatedly, Youngkin didn't fully approve but also didn't outright reject House Bill 1923, which would create more pay parity for midwives. In lieu of a signature, his amendment requires the Health Insurance Reform Commission conduct an assessment and that if the legislature accepts his tweaked version of the bill, it would be subject to reenactment next year.
Bolstering emergency responses, Youngkin also signed House Bill 1904 by Del. Rodney Willett, D-Henrico, which will allow midwives and nurse practitioners to be on 24-hour on-call duty rosters. The governor further approved House Bill 2753 by Del. Cliff Hayes, D-Chesapeake, which requires hospitals and outpatient birthing facilities to establish protocol for identifying and responding to obstetric emergencies. He also signed House Bill 2083 by Del. Irene Shin, D-Fairfax, which will establish a special enrollment period for qualified pregnant people on Virginia's health insurance exchange.
A survey the state conducted last year showed long wait times for new enrollees' paperwork to be processed. This contributed to delayed access to care for people to schedule their appointments.
Though Youngkin followed through on his stated goals of remedying maternal health care issues, for the second year in a row he is seeking an amendment on the unconscious bias training bill.
Senate Bill 740 by Sen. Mamie Locke, D-Hampton and House Bill 1649 by Hayes would require workers to complete unconscious bias and cultural competency training to renew medical licenses.
The bills have been carried for several years in a row. Last year, with bipartisan co-patrons and supporting votes, they reached Youngkin's desk where he also sought amendments before vetoing them.
Like last year, Youngkin's substitute strips the mention of cultural competency and unconscious bias, adding instead 'populations that data indicate experience significantly greater than average maternal mortality, postpartum complications and infant mortality.'
Governor unleashes veto storm to drown progressive legislation
Studies show that Black people are more likely to experience negative maternal health outcomes, in part, due to providers' racial bias. Black women are also more likely to die from pregnancy-related complications than white women, data from the Centers for Disease Control and Prevention shows.
Youngkin's substitute also would limit the training to two hours.
Locke, who has carried the Senate version of the bill for several years, said that 'no one can overcome unconscious bias and cultural incompetence by viewing a two-hour video.'
As she did last year, she plans to reject his substitute, which will likely garner another veto from the governor.
'My point to him is he needs to overcome his own implicit bias regarding Black maternal health issues,' Locke said. 'It is clear that he has no clue.'
While Youngkin has been supportive of doulas, which are key companions and advocates for parents-to-be, his amendment to a bill to expand doula state health insurance coverage postpartum left one of its patrons perplexed.
House Bill 1614 by Del. Adele McClure, D-Arlington, and Senate Bill 1418 by Sen. Lashrecse Aird, D-Petersburg, could allow for Virginia's health insurance to cover up to 10 doula visits — four during pregnancy and six afterwards.
Youngkin's substitute changes the semantics by removing the words 'birthing people' and changing it to 'birthing women.'
Though most pregnancies are experienced by cisgender women, transgender and nonbinary people with uteruses can still get pregnant, groups that the original language of the bill would have included. The governor's amendment also removed a provision referring to 'culturally appropriate and individualized care.'
Aird called it 'frustrating' to see the removal of culturally tailored care from her bill. She also said his fixation on gendered language is 'distracting from what really matters — getting people the care they need to improve outcomes and save lives.'
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
The Wistar Institute Receives $17 Million NIH Grant for Personalized HIV Cure Research
Philadelphia-led consortium is selected to tailor HIV curative strategies to participant Philadelphia, PA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The Wistar Institute announces the National Institutes of Health (NIH) granted a five-year, $17 million research award to launch iCure Consortium to develop individualized 'cure regimens' for HIV. The Wistar-led, iCure Consortium's objective is to advance strategies to cure HIV through tailored personalized medicine. 'Today 38 million people still live with HIV worldwide, and 1.3 million contract the virus each year,' said Luis J. Montaner, D.V.M., iCure principal investigator, executive vice president of The Wistar Institute and director of Wistar's HIV Cure and Viral Diseases Center. 'For the first time, this grant brings our best team together working towards a cure tailored to each participant by pairing the latest in neutralizing antibody and cell-therapy breakthroughs against the unique, person-specific features of HIV.' iCure Consortium will test a six-part, individually-tailored therapy designed to wipe out the persistent viral reservoir that remains after antiretroviral therapy in an effort to deliver durable, drug-free remission. The project combines six advanced tactics—neutralizing antibodies, mRNA therapy, viral binders, engineered CAR-T and 'Natural Killer' (NK) cells, and precision latency 'wake-up' drugs—all designed against each patient's unique virus. 'Ending HIV demands more than management—it demands eradication,' said Drew Weissman, M.D., Ph.D., iCure co‑principal investigator, 2023 Nobel Laureate and Roberts Family Professor in Vaccine Research at the Perelman School of Medicine at the University of Pennsylvania. 'This project now allows us to apply our breakthroughs in RNA therapy as part of a cure-directed strategy.' How iCure Works• Wake the latent virus• Map and target unique weak spots with tailored antibodies• Destroy infected cells using 'super‑charged' CAR‑T and NK cells• Enhance clearance and block relapse with bispecific binders In the first step, researchers reactivate the virus in a sample of the participant's blood and identify mutations that the participant has not yet developed antibodies against. They then develop a tailored antibody therapy cocktail specifically designed against these specific mutations. In the next stage, researchers focus on preventing HIV from returning. To do this, they develop person-specific antibodies or small molecule binders that can act as 'homing devices' — beacons that can lead immune cells to the latent virus. Then they genetically modify CAR-T cells and NK cells (immune cells that destroy viruses) to express or use these homing devices to better clear infected cells. Finally, researchers further enhance NK cells. First, they develop stronger and more durable cells, called adaptive NK cells, by supercharging their virus-killing ability. Then, they deploy small-molecule drugs called bispecifics, which bind NK cells to the infected cells they are targeting. "iCure takes full advantage of the advances made in understanding how and where HIV hides from the immune system," said Montaner. "We've built on our knowledge and can use that information to identify a first of its kind targeting to a person's unique HIV features." iCure furthers the research groundwork laid by the BEAT-HIV Martin Delaney Collaboratory ( a Philadelphia-based consortium of more than 95 leading HIV researchers co-led by Dr. Montaner. Montaner called the NIH grant a 'once in a lifetime opportunity' that reflects Wistar's track record as a scientific leader in the effort to develop an HIV cure, as well as its grassroots support and collaboration with the HIV community. 'By the end of this study we hope to have a process by which to identify the virus that we need to go after in each person and have a basis to design clinical trials choosing the best of these strategies to move forward,' said Montaner. Other institutions participating in this study include Johns Hopkins Medicine and iCure co-principal investigator Robert Siliciano, M.D., Ph.D., the University of Pennsylvania, Philadelphia FIGHT, the Ragon Institute at Harvard University, George Washington University, Duke University, and Massachusetts Institute of Technology. The iCure program is funded by the National Institute of Allergy and Infectious Diseases, part of NIH, under award number UM1AI191272. ### The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. CONTACT: Darien Sutton The Wistar Institute 215-870-2048 dsutton@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 hours ago
- Yahoo
Legislature overrides governor's veto to enact controversial law: 'An awful turning point'
Legislature overrides governor's veto to enact controversial law: 'An awful turning point' The North Carolina legislature overrode the governor's veto in order to approve a bill that could slow future environmental regulations. What's happening? Having already passed through the State House and Senate this past spring, House Bill 402 was vetoed by Democratic Governor Josh Stein in June. Republican lawmakers found enough votes to override the veto in late July, making it law, along with another seven previously vetoed bills. Also known as the Regulations from the Executive in Need of Scrutiny — or REINS — Act, HB 402 aims to place additional restrictions on the passage of any new environmental regulation in the state. According to North Carolina Health News, the new law will require any environmental regulation "with a projected financial impact" of $1 million over five years to be approved by a two-thirds majority of the body making the rule. For anything over $10 million, it requires unanimous approval. And for any regulation projected to cost $20 million or more, it requires formal approval from the state's General Assembly. Why is this concerning? This law could make it virtually impossible for any kind of real, substantive regulation to be implemented, environmental advocates say. "Lawmakers who passed this bill did not have the best interests of North Carolinians at heart," said Mary Maclean Asbill, director of the state's Southern Environmental Law Center's office. "This new law marks an awful turning point for families and communities across North Carolina when elected officials in the state legislature ignore serious illnesses and deaths in favor of polluters' profits," she continued in a release, per NCHN. The outlet noted that House Speaker Destin Hall, a Republican, said, "What we had in the REINS Act was a situation where if you have a regulation that is extremely expensive, our position is that it's something that [the legislature] needs to take a look at." Meanwhile, environmental advocates say that viewing each new regulation through a strictly financial lens — rather than through a lens that weighs the cost against the potential benefits for public health and essential ecosystems — will make passage of new legislation practically unobtainable. What's being done in North Carolina? While this legislation's finalization is certainly a blow to many environmentalists and public health advocates, their hopes are not completely lost in North Carolina. A pair of bills, HB 569 and Senate Bill 666, could still have major impacts on the state's environmental regulations, according to NCHN. Do you worry about having toxic forever chemicals in your home? Majorly Sometimes Not really I don't know enough about them Click your choice to see results and speak your mind. HB 569 would require polluters to reimburse public water systems for clean-ups of per- and polyfluoroalkyl substances. SB 666 would charge the Environmental Management Commission with setting regulatory limits on PFAS. It's unclear how either bill could be impacted by HB 402 becoming law, though, and the status of both bills remains uncertain at this stage. Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet. Solve the daily Crossword
Yahoo
14 hours ago
- Yahoo
This Cannabis Stock Just Transformed Into a Bitcoin Treasury Play. Should You Buy Shares Now?
It seems that companies whose products and services are not finding takers in the current market are pivoting at the drop of a hat to become Bitcoin (BTCUSD) treasury companies. While the most prominent among them has been the Michael Saylor-led MicroStrategy (MSTR), recently, two biotech companies have also 'rebranded' their business operations to load up on the world's largest cryptocurrency. Among the latest companies to join this bandwagon is cannabis company KindlyMD (NAKA). Valued at a market cap of $90 million, KindlyMD's shares have surged an impressive 742% in the year to date. More News from Barchart Trade the Warren Buffett Rally in UnitedHealth Stock With This High-Reward, Low-Risk Options Strategy Apple Expects $1.1 Billion Tariff Hit in 4th Quarter After $800 Million Q3 Hit; CEO Tim Cook Warns 'Many Factors That Could Change' Cathie Wood Is Buying BLSH Stock After the Bullish IPO. Should You? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. About KindlyMD Founded in 2019, KindlyMD is a Utah-based healthcare provider that specializes in alternative pain management, including through medicinal cannabis use. Its licensed clinicians integrate cannabis therapy into holistic care plans, positioning the company as one of the largest Qualified Medical Providers (QMPs) within Utah's regulated medical cannabis framework. But this is all set to go up in smoke as the company has been acquired by Bitcoin-centric investment firm Nakamoto Holdings. After the merger, the combined company will operate with the KindlyMD name and with the ticker symbol NAKA. The whole transaction generated $540 million in gross proceeds through a private placement in public equity (PIPE) financing, with a $200 million convertible note also closed. Thus, with a $740 million war chest, the company aspires to acquire 1 million BTC. Commenting on the deal, CEO David Bailey said, 'Our vision is for the world's capital markets to operate on a Bitcoin standard. Today's merger represents the beginning of that journey for our company.' Bailey will continue to remain the CEO of the merged entity. Co-founder of KindlyMD and ex-CEO Tim Pickett was also upbeat about the deal, saying, 'We are thrilled to officially close our merger with Nakamoto. We've built KindlyMD on operational and innovative excellence, and we are now extending that same principle to our capital strategy. Bitcoin gives us the ability to preserve value with the same integrity we apply to delivering care.' So, that begs the question: Is NAKA stock a viable investment option now? KindlyMD Posts Widening Losses, Declining Revenues KindlyMD reported revenues of $408,527 in Q2 2025, down 36.1% from the previous year, while net losses widened dramatically to $2.4 million from $1.3 million in the year-ago period. Operational losses also increased, coming in at $2.4 million compared to just over $1 million in the same period a year ago. Net cash outflow from operating activities widened to $2.8 million from $1.1 million in the year-ago period as the company closed the quarter with a cash balance of $6.02 million. This was higher than its total debt levels of $432,978. The Bottom Line After the merger, KindlyMD and NAKA stock look like little more than a passing fad. Just a company that is hoping to take advantage of the Bitcoin treasury momentum as a trade, with no solid operational plans. Thus, avoiding NAKA shares would be a wise choice on the part of investors. On the date of publication, Pathikrit Bose did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data